Healthcare, Regulatory and Reimbursement Landscape – Netherlands

This report is an essential source of information and analysis regarding the healthcare, regulatory, and reimbursement landscape in the Netherlands.
 
 
Dec. 12, 2012 - PRLog -- With the elderly making up an ever greater share of the country’s population, the Netherlands is increasingly supporting its generics sector in an attempt to address mounting healthcare costs, says a new report from industry experts GlobalData.

The firm’s latest publication* shows that the percentage of Dutch citizens aged 65 and over has climbed from 14.1% in 2006 to 15.6% last year, and is expected to further increase to 18.6% by the end of the decade – unavoidably increasing the demand on the nation’s healthcare resources.

In a bid to cut the country’s healthcare deficit, the Netherlands is focusing on the use of generics as a cost-containment tool. In 2008, health insurers introduced preference policies, which contain lists of medicines that have the same composition (or active substance), but differ in price. This resulted from health insurers’ preference to reimbursing these less expensive medications. Consequently, the prices of commonly-used generic drugs fell by an average of 85% the following year.

In addition, the government allowed insurers to add biosimilar drugs in their preference policies in 2009, providing further momentum to the country’s expanding generics market.

For Sample Pages, please click or add the below link to your browser:

http://www.globaldata.com/reportstore/RequestSamplePages....

Thanks in part to this system, the generic pharmaceutical market in the Netherlands increased in value from US$832m in 2005 to an estimated US$1.8 billion in 2010, at a Compound Annual Growth Rate (CAGR) of 15%.

With several major drugs going off-patent in the near future, GlobalData expects the Dutch generics sector to continue its impressive expansion, providing fantastic opportunities for the country’s generics manufacturers.

This report is an essential source of information and analysis regarding the healthcare, regulatory, and reimbursement landscape in the Netherlands.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GlobalData’s team of industry experts.

GlobalData is a leading global business intelligence provider offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries.

For further details, please click or add the below link to your browser:

http://www.globaldata.com/reportstore/Report.aspx?ID=Heal...

Visit our report store:

http://www.globaldata.com/reportstore

For more details contact:pressreleases@globaldata.com


North America:          +1 646 395 5477

Europe:          +44 207 753 4299

         +44 1204 543 533
Asia Pacific:          +91 40 6616 6782
End
Source:
Email:***@globaldata.com Email Verified
Phone:+914066166782
Zip:EC4Y 0AN
Tags:Healthcare, Regulatory, Reimbursement Landscape, Pharmaceuticals_and_healthcare
Industry:Health
Location:London City - London, Greater - United Kingdom
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
GlobalData News
Trending
Daily News
Weekly News



Like PRLog?
9K2K1K
Click to Share